Royal Fund Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Royal Fund Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.4M	Sell	154,465 -8,385	-5%	-$1.13M	2.04%	3
2026 Q1	$20.8M	Buy	162,850 +19,137	+13%	+$2.39M	1.98%	4
2025 Q4	$17.5M	Buy	+143,713	New	+$16.5M	1.59%	10
2025 Q3	–	Sell	-67,521	Closed	-$5.6M	–	355
2025 Q2	$5.6M	Buy	67,521 +4,208	+7%	+$336K	0.56%	55
2025 Q1	$5.13M	Buy	63,313 +713	+1%	+$63.7K	0.57%	55
2024 Q4	$5.64M	Sell	62,600 -233,886	-79%	-$22.7M	0.53%	58
2024 Q3	$29.3M	Buy	296,486 +235,835	+389%	+$23.2M	1.75%	9
2024 Q2	$5.62M	Buy	+60,651	New	+$5.44M	0.46%	41
2018 Q1	–	Sell	-102	Closed	-$8K	–	727
2017 Q4	$8K	Buy	+102	New	+$8.54K	﹤0.01%	418

Other funds holding XBI

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

Parkside Investments Deerfield, Illinois $902M AUM 32.45% 1-Year Est. Return

Royal Fund Management's XBI Position: Q2 2026 in Review

Royal Fund Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 5.1% in Q2 2026, selling an estimated $1.13M and leaving 154,465 shares worth $24.4M. The position accounts for 2.04% of the portfolio, ranked #3.

Royal Fund Management first reported a position in XBI in Q4 2017 and has held it in 9 quarters since. The position peaked at $29.3M in Q3 2024. 154 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Royal Fund Management held 154,465 shares of State Street SPDR S&P Biotech ETF worth $24.4M as of Q2 2026.
Royal Fund Management sold 8,385 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.13M.
State Street SPDR S&P Biotech ETF made up 2.04% of Royal Fund Management's portfolio in Q2 2026, its #3 holding.
Royal Fund Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 9 quarters since.
Royal Fund Management's State Street SPDR S&P Biotech ETF position peaked at $29.3M in Q3 2024.
154 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.